| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
Effects of the chymase inhibitor were evaluated on animal models with the non-alcoholic steatohepatitis (NASH) and stroke-prone spontaneously hypertensive (SHR-SP) rats as complications of the metabolic syndrome. In a hamster NASH model, plasma levels of AST and ALT were improved by the chymase inhibitor and the improvement of lipid deposition and fibrosis was also observed. In SHR-SP rats, the chymase inhibitor showed to prevent the vascular endothelial dysfunction via the anti-oxidative effect and the prevention of inflammatory cell-infiltration into the endothelium without hypotensive effect. The chymase inhibitor also extended the survival term.
These results suggest that chymase inhibition become the useful strategy to prevent the complication of metabolic syndrome.
|
